# SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

> **NCT06266871** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** SOX+Tislelizumab+LDRT

## Key facts

- **NCT ID:** NCT06266871
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06266871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06266871, "SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06266871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*